Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) is scheduled to be announcing its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.91) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.08). The firm had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.47 million. The company’s revenue was down 59.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.94) EPS. On average, analysts expect Crinetics Pharmaceuticals to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Crinetics Pharmaceuticals Stock Up 0.2 %
CRNX opened at $56.82 on Tuesday. Crinetics Pharmaceuticals has a 52 week low of $25.75 and a 52 week high of $60.04. The company has a market cap of $4.55 billion, a PE ratio of -15.03 and a beta of 0.62. The business has a 50 day moving average price of $53.78 and a two-hundred day moving average price of $50.25.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Report on Crinetics Pharmaceuticals
Insider Activity at Crinetics Pharmaceuticals
In other Crinetics Pharmaceuticals news, CFO Marc Wilson sold 25,000 shares of the company’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $51.11, for a total value of $1,277,750.00. Following the transaction, the chief financial officer now directly owns 111,092 shares of the company’s stock, valued at $5,677,912.12. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, insider Dana Pizzuti sold 14,375 shares of the stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $54.63, for a total value of $785,306.25. Following the completion of the transaction, the insider now owns 28,507 shares in the company, valued at approximately $1,557,337.41. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Marc Wilson sold 25,000 shares of Crinetics Pharmaceuticals stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $51.11, for a total value of $1,277,750.00. Following the transaction, the chief financial officer now directly owns 111,092 shares of the company’s stock, valued at approximately $5,677,912.12. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 43,410 shares of company stock valued at $2,275,929. Insiders own 6.00% of the company’s stock.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.
Featured Articles
- Five stocks we like better than Crinetics Pharmaceuticals
- Manufacturing Stocks Investing
- Intel: Is Now the Time to Be Brave?Â
- Insider Trading – What You Need to Know
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- How to Effectively Use the MarketBeat Ratings Screener
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.